- Conditions
- Angioedema
- Interventions
- Icatibant, Placebo
- Drug
- Lead sponsor
- Shire
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 84 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2006
- U.S. locations
- 1
- States / cities
- Washington D.C., District of Columbia
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–11
of 11
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Hereditary Angioedema (HAE)
- Interventions
- Icatibant (30 mg)
- Drug
- Lead sponsor
- Shire
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014
- U.S. locations
- 1
- States / cities
- Glendale, California
- Conditions
- Hereditary Angioedema (HAE)
- Interventions
- icatibant
- Drug
- Lead sponsor
- Shire
- Industry
- Eligibility
- 2 Years to 17 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2018
- U.S. locations
- 12
- States / cities
- Los Angeles, California • Tampa, Florida • Shreveport, Louisiana + 9 more
- Conditions
- Hereditary Angioedema
- Interventions
- Icatibant, Placebo
- Drug
- Lead sponsor
- Shire
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 98 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 39
- States / cities
- Alabaster, Alabama • Birmingham, Alabama • Scottsdale, Arizona + 35 more
- Conditions
- Angioneurotic Edema
- Interventions
- HOE-140, Placebo
- Drug · Other
- Lead sponsor
- Vanderbilt University
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2015
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- ACE Inhibitor-associated Angioedema
- Interventions
- icatibant, Placebo
- Drug · Other
- Lead sponsor
- Vanderbilt University Medical Center
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2016
- U.S. locations
- 2
- States / cities
- San Diego, California • Nashville, Tennessee
- Conditions
- Angiotensin Converting Enzyme Inhibitor Induced Angioedema
- Interventions
- Icatibant, Placebo
- Drug
- Lead sponsor
- Shire
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 118 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 43
- States / cities
- La Jolla, California • Washington D.C., District of Columbia • Gainesville, Florida + 31 more
- Conditions
- Cardiopulmonary Bypass, Inflammation, Fibrinolysis, Surgery
- Interventions
- HOE 140, Aminocaproic Acid, Placebo
- Drug
- Lead sponsor
- Vanderbilt University
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2012
- U.S. locations
- 2
- States / cities
- Nashville, Tennessee
- Conditions
- Intradialytic Hypotension
- Interventions
- Icatibant, Placebo
- Drug
- Lead sponsor
- Vanderbilt University Medical Center
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Hereditary Angioedema
- Interventions
- Icatibant
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 5
- States / cities
- La Jolla, California • Los Angeles, California • Wheaton, Maryland + 2 more
- Conditions
- COVID-19
- Interventions
- Remdesivir, Imatinib Mesylate, Dexamethasone, Cenicriviroc, Icatibant, Apremilast, dornase alfa, Celecoxib, Famotidine, IC14, Aviptadil, narsoplimab, Cyproheptadine, Cyclosporine
- Drug · Biological
- Lead sponsor
- QuantumLeap Healthcare Collaborative
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1,500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2030
- U.S. locations
- 36
- States / cities
- Birmingham, Alabama • Davis, California • Irvine, California + 30 more